Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 8/20 | 0.66 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.59 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.59 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1585406 | 0.98 | FDPS (0.64) | FDPSBTN3A1PDE3ANAPRTCYP1A2 | |
| SCHEMBL1585411 | 0.98 | FDPS (0.64) | FDPSBTN3A1PDE3ANAPRTCYP1A2 | |
| SCHEMBL5661023 | 0.81 | FDPS (0.62) | FDPSBTN3A1PDE3ANAPRTCHRNA7 | |
| SCHEMBL31061112 | 0.79 | FDPS (1.00) | FDPSBTN3A1PDE3ANAPRTCYP1A2 | |
| SCHEMBL2459769 | 0.79 | FDPS (1.00) | FDPSBTN3A1PDE3ANAPRTCYP1A2 | |
| SCHEMBL1585408 | 0.78 | FDPS (0.50) | FDPSBTN3A1PDE3ANAPRTCYP1A2 | |
| SCHEMBL207656 | 0.76 | FDPS (0.56) | FDPSBTN3A1PDE3ANAPRTCYP1A2 | |
| SCHEMBL30102567 | 0.76 | FDPS (0.56) | FDPSBTN3A1PDE3ANAPRTCYP1A2 | |
| SCHEMBL2467559 | 0.75 | FDPS (0.59) | FDPSBTN3A1PDE3ANAPRT | |
| SCHEMBL7863043 | 0.75 | FDPS (0.69) | FDPSBTN3A1PDE3ANAPRTTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119978387-A | Three-component synthesis method of polyphosphonate | 华南理工大学 | 2025-05-13 | — | — | CN | claimed |
| CN-122029970-A | Photoelectric conversion element and solar cell module | 株式会社安能科多科技 | 2026-05-12 | — | — | CN | disclosed |
| US-20250386657-A1 | PHOTOELECTRIC CONVERSION ELEMENT | ENECOAT TECH CO LTD (JP) | 2025-12-18 | — | — | US | disclosed |
| EP-4646077-A1 | PHOTOELECTRIC CONVERSION ELEMENT | Enecoat Technologies Co., Ltd. (JP) | 2025-11-05 | — | — | EP | disclosed |
| WO-2025110210-A1 | PHOTOELECTRIC CONVERSION ELEMENT AND SOLAR CELL MODULE | 株式会社エネコートテクノロジーズ | 2025-05-30 | — | — | WO | disclosed |
| CN-119978387-A | Three-component synthesis method of polyphosphonate | 华南理工大学 | 2025-05-13 | — | — | CN | disclosed |
| CN-119487998-A | Photoelectric conversion unit | 株式会社安能科多科技 | 2025-02-18 | — | — | CN | disclosed |
| WO-2024143549-A1 | PHOTOELECTRIC CONVERSION ELEMENT | 株式会社エネコートテクノロジーズ | 2024-07-04 | — | — | WO | disclosed |
| US-20240055382-A1 | METALLIZATION METHOD | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2024-02-15 | — | — | US | disclosed |
| CN-117457484-A | Metallization method | 罗门哈斯电子材料有限责任公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20170003275-A1 | METHOD TO IDENTIFY COMPOUNDS ABLE TO BIND TO THE ROSSMANN FOLD OF C-TERMINAL-BINDING PROTEINS, IDENTIFIED COMPOUNDS AND MEDICAL USES THEREOF | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 2017-01-05 | — | — | US | disclosed |
| WO-2014184370-A1 | METHOD TO IDENTIFY COMPOUNDS ABLE TO BIND TO THE ROSSMANN FOLD OF C-TERMINAL-BINDING PROTEINS, IDENTIFIED COMPOUNDS AND MEDICAL USES THEREOF | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 2014-11-20 | — | — | WO | disclosed |
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2013-03-14 | — | — | US | disclosed |
| WO-2011046920-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2011-04-21 | — | — | WO | disclosed |
| CN-1087092-A | Novel 7 beta-substituted-4-aza-5 alpha-androstan-3-ones as 5 alpha-reductase inhibitors | MERCK & CO INC (US) | 1994-05-25 | — | — | CN | disclosed |
| WO-1993023039-A1 | SUBSTITUTED 4-AZA-5A-ANDROSTAN-ONES AS 5A-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | DDX18, FPR1, DCXR | FDPS 167/4885BTN3A1 4095/4885PDE3A 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.